prevail
therapeutics
receives
fda
fast
track
designation
treatment
neuronopathic
gaucher
disease
new
york
globe
newswire
prevail
therapeutics
nasdaq
prvl
biotechnology
company
developing
potentially
gene
therapies
patients
neurodegenerative
diseases
today
announced
food
drug
administration
fda
granted
fast
track
designation
company
experimental
gene
therapy
program
treatment
neuronopathic
gaucher
disease
ngd
company
expects
initiate
enrollment
provide
phase
clinical
trial
type
neuronopathic
gaucher
disease
patients
second
half
fda
fast
track
designation
treatment
neuronopathic
gaucher
disease
underscores
significant
unmet
medical
need
devastating
condition
currently
approved
therapies
said
asa
abeliovich
founder
chief
executive
officer
prevail
type
gaucher
disease
involves
rapidly
progressive
neurodegeneration
leading
death
infancy
early
childhood
type
gaucher
disease
associated
significant
neurological
manifestations
including
seizures
motor
abnormalities
believe
potential
serve
therapeutic
option
patients
enzyme
replacement
therapies
approved
type
gaucher
disease
cross
blood
brain
barrier
address
neurological
fda
previously
granted
rare
pediatric
disease
designation
treatment
ngd
orphan
drug
designation
treatment
patients
gaucher
disease
addition
fda
granted
fast
track
designation
treatment
parkinson
disease
mutations
fast
track
designation
fda
fast
track
designation
process
designed
expedite
facilitate
review
product
candidates
treat
serious
conditions
fill
unmet
medical
need
fast
track
designation
allows
early
frequent
communication
fda
throughout
entire
drug
development
review
process
may
also
allow
priority
rolling
review
company
biologics
license
application
bla
neuronopathic
gaucher
disease
gaucher
disease
lysosomal
storage
disorder
caused
mutations
glucocerebrosidase
gene
leading
pathology
patients
severe
mutations
gene
present
neuronopathic
gaucher
disease
also
termed
type
type
gaucher
disease
type
gaucher
disease
presents
infancy
involves
rapidly
progressive
neurodegeneration
leading
death
infancy
early
childhood
type
gaucher
disease
typically
presents
childhood
involve
neurological
manifestations
seizures
gaze
motor
abnormalities
therapies
approved
fda
treatment
neuronopathic
gaucher
disease
prevail
therapeutics
prevail
gene
therapy
company
leveraging
breakthroughs
human
genetics
goal
developing
commercializing
gene
therapies
patients
neurodegenerative
diseases
company
developing
patients
parkinson
disease
mutations
neuronopathic
gaucher
disease
ngd
patients
frontotemporal
dementia
grn
mutations
patients
certain
synucleinopathies
prevail
founded
asa
abeliovich
collaborative
effort
silverstein
foundation
parkinson
gba
orbimed
headquartered
new
york
ny
statements
related
prevail
statements
contained
press
release
regarding
matters
historical
facts
statements
within
meaning
private
securities
litigation
reform
act
amended
examples
statements
include
statements
concerning
potential
advantages
fast
track
designation
potential
serve
potentially
therapeutic
option
patients
neuronopathic
gaucher
disease
statements
subject
risks
uncertainties
actual
results
may
differ
materially
expressed
implied
statements
risks
uncertainties
include
among
others
prevail
novel
approach
gene
therapy
makes
difficult
predict
time
cost
potential
success
product
candidate
development
regulatory
approval
prevail
gene
therapy
programs
may
meet
safety
efficacy
levels
needed
support
ongoing
clinical
development
regulatory
approval
regulatory
landscape
gene
therapy
rigorous
complex
uncertain
subject
change
fact
gene
therapies
novel
complex
difficult
manufacture
risks
relating
impact
business
pandemic
similar
public
health
crises
risks
described
fully
prevail
filings
securities
exchange
commission
sec
including
risk
factors
section
company
quarterly
report
form
period
ended
june
filed
sec
august
documents
subsequently
filed
furnished
sec
statements
contained
press
release
speak
date
made
except
extent
required
law
prevail
undertakes
obligation
update
statements
reflect
events
occur
circumstances
exist
date
made
media
contact
lisa
qu
ten
bridge
communications
lqu
investor
contact
investors
